The ribosome is an RNA-protein complex essential for translation in all domains of life. The structural and catalytic core of the ribosome is its ribosomal RNA (rRNA). While mutations in ribosomal protein (RP) gene are known drivers of oncogenesis, oncogenic rRNA variants have remained elusive.
Introduction
The ribosome is a massive ribonucleoprotein particle (RNP) responsible for the transformation of genetic information encoded as nucleic acids into functional proteins encoded as amino acids. Unlike most RNPs, it is ribosomal RNA (rRNA), and not ribosomal proteins (RPs) that form the most ancient and catalytic core of the complex 1 . rRNA is further functionalized by a constellation of at least 14 distinct chemical modifications across 200+ sites, 2 clustering around active sites of the ribosome 3 , yet the function of many rRNA modifications remain unclear.
The human ribosome contains >80 RPs and four rRNAs, totaling ~80% of cellular RNA. During the initial human genome sequencing project, ribosomal DNA (rDNA) loci were systematically excluded from the reference genome 4 ; given that a reference sequence of the rRNA gene, RNA45S, was available and the 80-800 rDNA copies were believed to be homogeneous 5 , although there was early evidence for rDNA polymorphism in humans 6, 7 . Thus, as technology and sequencing consortium projects revolutionized genomics and transcriptomics, our understanding of rDNA variation has lagged.
rDNA sequence variation at the intra-and inter-individual level has been documented in multiple species including humans [8] [9] [10] [11] [12] , but the functional implications of rDNA variation remain elusive.
Mutation of RP genes and ribosome biogenesis factors can cause a class of diseases termed ribosomopathies, including Diamond Blackfan anemia (DBA) 13 , and some cancers 14 . It has been hypothesized that cancer cells contain a functionally specialized class of ribosomes to facilitate rapid protein synthesis, termed the "onco-ribosomes" 15, 16 . Cancer genomics has supported this notion with the identification of several oncogenic driver mutations in RP genes 14 , the best characterized of which are RPL10 (uL16) p.R98S in T-cell acute lymphoblastic leukemia 17, 18 and RPS15 (uS19) C' terminal mutations in chronic lymphocytic leukemia 19 . In addition, germline mutations such as in DBA patients and in RPS20 can cause heredity cancers including colorectal carcinoma (CRC) 20, 21 .
As RP mutations have been implicated in tumorigenesis, we hypothesized that rRNA variation or mutation is a cancer driver. To map functional rRNA sequence variation, we considered tumorigenesis as a natural experiment in which polymorphic and mutant rRNA alleles undergo selective evolutionary change in frequency within each patient. We discovered a surprising 18S rRNA single nucleotide variation at the decoding core of the ribosomal peptidyl (P)-site, affecting up to 45.9% of CRC patients, making this the most frequent ribosomal variant associated with cancer to date and potentially revolutionizing future chemotherapeutic strategies against this disease. 
Results & Discussion

An unexpected rRNA variant in cancer: sub-stoichiometric modification of 18S.1248.m 1 acp 3 Ψ
In an initial screen for cancer-driver rRNA variants, we aligned RNA-seq reads from 66 colorectal carcinoma (CRC) tumors and patient-matched adjacent normal tissue to a single-copy reference rDNA.
To test for allelic selection inconsistent with neutral drift, the patient-matched difference in expressed variant allele frequency (VAF) was measured for deviation from zero for each position of 18S and 28S ( Fig. 1a) . A single nucleotide variation deviated from neutrality, 18S:r.1248.U (p adj = 3.81e-8). The 18S.1248.U variation is recurrent selection over non-U or 18S.1248V alleles in a striking 44.9% of CRC patients (Fig. 1a ); in comparison, oncogenic KRAS G12 codon mutation occurs in only 36% of CRC patients 22 . Surprisingly, at the DNA level, RNA45S:1248.T is invariable in humans 10 and in the mature rRNA this uridine undergoes hyper-modification to 1-methyl-3-α-amino-α-carboxyl-propyl pseudouridine (m 1 acp 3 Ψ), a mo ) ( Fig. 1b) 2 . The m 1 acp 3 Ψ), a mo modification perturbs standard Watson-Crick base-pairing during cDNA synthesis by reverse transcriptase (RT) 23 , resulting in base misincorporation and enzyme stalling, which is read-out as a consistent 'modification signature' in RNA-seq ( Fig. 1c , reviewed in 23 ). The increase in reference U sequence suggests that the m 1 acp 3 Ψ), a mo modification is incomplete or substoichiometric in CRC tumors, which we term the 'hypo-m 1 acp 3 Ψ), a mo phenotype'. The 28S.1321.m 1 A and 28S.4532.m 3 U rRNA modifications also cause a 'modification signature' in RNA-seq 23 . These modifications do not decrease in CRC tumors or matched normal controls, excluding a non-specific rRNA modification effect (Fig. 1d ).
The hypo-m 1 acp 3 Ψ), a mo phenotype is reproducible at comparable frequency (27.8-45 .9%) in three additional independent patient-matched CRC cohorts ( Fig. 1e ,f). Analysis of 10,036 cancer patients and 712 normal controls across an additional 31 cancer-patient cohorts reveals that hypo-m 1 acp 3 Ψ), a mo occurs at a significant frequency across a diverse set of cancers, but is not pan-cancerous (global recurrence: 9.6% range: 0-52.8%) ( Fig. 1f , S1).
To validate these findings, we designed a simple and rapid RT-PCR m 1 acp 3 Ψ), a mo assay for measuring 18S.1248.m 1 acp 3 Ψ), a mo modification. The m 1 acp 3 Ψ), a mo assay is reproducible and quantitative ( Fig. S2 ). An important technical limitation is that different RT enzymes have different base misincorporation rates at 18S.1248.m 1 acp 3 Ψ), a mo , thus, cross-cohort or cross-experimental comparisons should be made cautiously, including in RNA-seq ( Fig. S2b-d) . Indeed, batch-effects on VAF are seen within TCGA cohorts, but hypo-m 1 acp 3 Ψ), a mo replicates across batches, further supporting that hypo-m 1 acp 3 Ψ), a mo is occurring in tumors specifically ( Fig. S1b ).
We validated that the hypo-m 1 acp 3 Ψ), a mo phenomenon also occurs in CRC cell lines assayed as a single batch and confirmed the results are not a sequencing artifact ( Fig. S2e ). To test if m 1 acp 3 Ψ), a mo -deficient rRNA incorporate into mature ribosomes, we isolated monosomes and polysomes and detected low m 1 acp 3 Ψ), a mo modification levels in mono-and di-somes ( Fig. S2f ). As the molecular, biological, and medical significance of 18S.1248.m 1 acp 3 Ψ), a mo unfolds, it is obvious that genotyping technologies (such as sequencing or our m 1 acp 3 Ψ), a mo assay) and previous m 1 acp 3 Ψ), a mo assays such as primer extension can be adapted as affordable and rapid diagnostic or prognostic assays.
18S:1248.m 1 acp 3 Ψ is an ancient modification at the P-site core
We next investigated the evolutionary and structural characteristics of 18S.1248.m 1 acp 3 Ψ), a mo for functional insight. The 18S:1248.U base and m 1 acp 3 Ψ), a mo modification are absolutely conserved across Eukarya at a residue located in the loop of universal helix 31 ( Fig. S3 ). TSR3 is the aminocarboxylpropyl transferase which deposits the acp 3 at 18S.1248.U 24 and it only modifies this single rRNA position, in 100% of mature rRNA molecules 25, 26 .
Structurally, 18S.1248.m 1 acp 3 Ψ), a mo is solvent-exposed at the ribosomal P-site, immediately adjacent to the codon:anti-codon interface (Fig. 2 ). Cryo-EM structures 27, 28 and our molecular dynamics (MD) simulations implicate the m 1 acp 3 -modification in a direct interaction with P-site tRNA with the carboxyl-moiety forming a hydrogen bond with the universally conserved RPS16 p.R146 29 and reducing 18S rRNA flexibility at the decoding site ( Fig. S4 ).
Start AUG-codon selection and translational initiation is a rate-limiting step in protein-synthesis and both occur at the P-site. Thus, the hypo-m 1 acp 3 Ψ), a mo phenotype may demarcate a class of 'onco-ribosome' with deregulated translation. It is noteworthy that the two largest effect size RP cancer driver mutations also occur at the ribosomal P-site/tRNA interface, the RPL10 p.R98S at the peptidyl transfer site 17, 18 and RPS15 C` tail mutations adjacent (<12Å) to 1248.m 1 acp 3 Ψ), a mo ( Fig. 2a ) suggesting that the ribosomal P-site is a convergent multi-cancer oncogenic hot-spot.
Since the discovery of streptomycin in 1944, the ribosome has been the target of several important classes of drugs 30 . The pervasive and recurrent loss of a solvent-exposed and charged acp 3 modification at the decoding core of the small sub-unit raises the possibility that this pocket may be therapeutically 
Loss of 18S.1248.m 1 acp 3 Ψ modification induces ribosomal protein mRNA translation
To delineate the function of 18S.1248.m 1 acp 3 Ψ), a mo , we generated TSR3 knockout CRC cell lines (HCT116). Similar to yeast 24 , TSR3 is non-essential and we isolated two TSR3 homozygous knockouts (TSR3[ KO 1, 3] ), a heterozygous knockout (TSR3[Het 2]), as well as three wildtype control clones (WT [1] [2] [3] ). Knockouts were functionally confirmed by three independent m 1 acp 3 Ψ), a mo assays, with To validate if this RP mRNA/protein signature is present in patients, we analyzed the CPTAC-CRC cohort with tumor matched RNA-seq and proteomics data 31 . Similar to TSR3[KO]/[Het] cell lines, hypo-m 1 acp 3 Ψ), a mo CRC tumors share the same E2F oncogenic gene signature and a proteomic increase in RPs relative to normo-m 1 acp 3 Ψ), a mo CRC tumor controls ( Fig. 3e,f ).
There are two hypotheses with which to interpret the hypo-m 1 acp 3 Ψ), a mo phenotype. The 'oncogenic driver hypothesis' is that m 1 acp 3 Ψ), a mo -deficient rRNA arise in tumorigenesis, and their dysregulated translation confers a selective advantage to the cancer, likely via high RP output. The recapitulation of the fitness. Nevertheless, hypo-m 1 acp 3 Ψ), a mo is a highly recurrent pertubation to the ancient peptidyl-decoding core and underlies a greater cancer-translational phenomenon.
Conclusions
Ribosomes are the fulcrum in the central dogma of molecular biology. Multi-omics studies have repeatedly highlighted the discordance between mRNA and protein abundance 32, 33 , emphasizing the role of translational variability in physio-normal and pathological states. Several recent studies have begun to resolve the ribosome from a uniform assembly into a rich tapestry of functionally heterogeneous complexes making up distinct translational compartments in the cell 15, 16, [34] [35] [36] [37] . We have discovered a pervasive and cancer-specific 'onco-ribosome' marked by loss of rRNA m 1 acp 3 Ψ), a mo modification. Enticingly, the cancer-specific m 1 acp 3 Ψ), a mo -deficient ribosomes are exceptionally recurrent and can be explored as a novel chemotherapeutic class. 
Data and code availability
Sequencing data generated in this study is available on NCBI SRA (pending accession). Electronic laboratory notebook for these experiments and analysis scripts are available at https://www.github.com/ ababaian/ C rown . 0.1) genes. g, MA-plot for total translation, highlighting the ribosome and RB/E2F gene sets. h, P-site occupancy was calculated over all expressed coding sequences (CDS). Globally, there was no significant difference between P-site occupancy per codon in WT [1] [2] [3] 
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Materials & Methods
Ribosomal sequence alignment and variant allele frequency calculations
DNA and RNA-seq libraries used in this study were prepared via poly-A selection to enrich for thẽ 5% of mRNA from total RNA. Since rRNA is ~80% of cellular RNA it invariably 'contaminates'
RNA-seq libraries. Typically, poly-(A) RNA-seq libraries contain 3.55% (+/-0.685, 95% CI, CRC I cohort, N = 66) of total reads aligned to rDNA. A complete list of library accessions used in this study is available in table S1 [42] [43] [44] [45] .
Libraries were aligned to the hgr1 reference rDNA sequence 10 
Transcriptome and translatome alignment, assembly and differential expression
RNA-seq reads were aligned to hg38 (GRCh38) reference genome with tophat2 (v.2.0.14) 48 . Individual transcriptome assemblies for HCT116 [WT 1-3], [ KO 1, 2] and [Het 2] libraries were generated with stringtie (v 2.0) 49 , and then all merged together with the human gencode basic gene annotation (v. 31) 50 ultimately yielding the hct116_gencode.v31 reference gene set.
To generate a single-copy reference transcriptome for ribo-seq analysis of HCT116, isoform-specific quantification of gene expression was performed on the hct116_gencode.v31 gene set with `stringtie -G hct116_gencode.gtf`. For each gene with non-zero expression (>10 unique reads), the one highest For ribo-seq alignment, after read adapter trimming and alignment to hgr1 as above, unmapped reads were aligned against a containment file containing human tRNA, mtDNA, snoRNA, snRNA and miRNA sequences. Reads remaining unmapped were then aligned to hg38 and the All bioinformatic analyses were scripted for reproducibility and are available at https://www.github.com/ababaian/crown.
HCT116 cell culture and TSR3 knockout
The colorectal carcinoma cell line HCT116 (CCL-247, ATCC, Manassas, VA) was cultured in DMEM media (#36250, STEMCELL Technologies, Vancouver, Canada) supplemented with 10% fetal bovine serum (F1051, Invitrogen, Waltham, MA).
To generate TSR3 knockouts, 10 5 HCT116 cells were transfected with 10 nmol of one of three TSR3 targeting Alt-R CRISPR-Cas9 ribonucleoproteins or non-targeting controls (table S2) Each system underwent a steepest descent minimization of water for 10,000 steps then water and ions for 100,000 steps twice followed by minimization of nucleic acid and protein for 50,000 steps and finally the whole system for 100,000 steps. After minimization all systems were equilibrated to 300 and 350 K for 150 ps. Coordinates of the 350 K equilibration in conjunction with velocities from the 300 K equilibration were used as initial parameters for the MD simulation. Each system was simulated for 20ns. Energy contributions of 18S.1248.m 1 acp 3 Ψ), a mo or 18S.1248.U were determined with the NAMD Energy package 65 . 
Statistics
